Press Releases Synairgen plc

Equities

SNG

GB00B0381Z20

Market Closed - London S.E. Other stock markets 11:35:18 2024-05-31 am EDT			5-day change	1st Jan Change
6.91 ^GBX	-0.58%		+2.67%	+15.65%

May. 07	AstraZeneca target raised; Antofagasta lowered	AN
2023	FTSE 100 Finishes Slightly Lower After Steady Session	DJ

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Synairgen : IDWeek 2023 Poster Presentation	23-10-12	PU
Synairgen looking beyond COVID in fight against respiratory illness	23-09-21	AQ
Synairgen : Interim Results	23-09-21	PU
Synairgen : ATS 2023 SPRINTER Poster Presentation	23-05-23	PU
Synairgen : 2022 Annual Report	23-05-23	PU
Synairgen CEO lays out plans for 2023 and beyond	23-04-28	AQ
Synairgen : Board Changes	22-12-01	PU
Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19	22-10-04	BU
Synairgen : Presentation at Disease Prevention and Control Summit, 7 September 2022, no audio	22-09-28	PU
Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022	22-09-20	BU
Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients	22-09-07	BU
Synairgen : FY21 Preliminary Results Presentation 25 May 2022	22-05-26	PU
Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022	22-05-16	BU
Synairgen shares tumble 84 per cent as Covid-19 treatment misses mark	22-02-22	AQ
Synairgen : Topline results from Phase 3 SPRINTER trial	22-02-21	PU
Synairgen : 8th December 2021 ESWI presentation demonstrates interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern	21-12-08	PU
Synairgen : 7th December 2021 ESWI presentation demonstrates interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern	21-12-07	PU
11th November 2021 Synairgen completes Phase III recruitment	21-11-11	PU
Synairgen : announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial	21-10-20	AQ
Synairgen : 20th October 2021 SNG001 progresses to Phase 3 of ACTIV-2 trial	21-10-20	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Synairgen plc

Equities

SNG

GB00B0381Z20

Press Releases

Filters